JOHANNESBURG, Gauteng — In a decisive move to protect public health, the South African Health Products Regulatory Authority (SAHPRA) is intensifying its fight against fake medicines flooding the South Africa market. Mokgadi Fafudi, SAHPRA’s regulatory compliance manager, warns that organized criminal syndicates are aggressively distributing falsified and substandard chronic and lifestyle medications, urging citizens to remain highly vigilant about where they source their treatments.
The shadow economy is taking a massive toll on the nation, siphoning an estimated R700 billion from South Africa’s GDP annually. Within this broader illicit landscape, regulators estimate that up to 15% of the fast-moving consumer goods market is currently non-compliant or entirely illicit. High-demand pharmaceuticals, including vital HIV treatments, antibiotics, pain management drugs, and popular weight-loss injections, are the primary targets of these underground networks.
Fafudi candidly acknowledged that eradicating this black market is an uphill battle, bordering on impossible, given the constrained resources available to health regulators. Because of this reality, the newly expanded public education blitz places the onus squarely on patients. Consumers must actively verify that their medical products are sourced from authorized, reliable supply chains and approved healthcare practitioners.
Identifying counterfeit health products requires recognizing clear warning signs. Fafudi explicitly cautioned against obtaining any injectable treatments—such as vitamin drips at IV bars, steroids, or growth enhancers—at gyms, beauty salons, bars, or unlicensed home-based aesthetic clinics. By law, any injectable is classified as a minimum Schedule 3 substance, mandating a valid prescription and administration by a registered medical professional or authorized clinic.
Furthermore, she stressed that legitimate medicines are never sold through online platforms. While local corner stores (T-shops) may stock basic remedies for minor ailments like a mild headache, they are entirely unsuitable for dispensing body-altering or curative therapies.
While the National Consumer Commission works to roll out the country’s inaugural track-and-trace framework under the Consumer Protection Act, SAHPRA is advancing its own multi-stakeholder national action plan. Initiated last year, this coalition brings together law enforcement, educators, supply chain operators, medical professionals, and consumer advocacy groups to systematically dismantle illicit operations and enforce punitive measures against offenders.
Tracing the origin of these dangerous goods remains highly complex. Fafudi revealed that syndicates frequently smuggle active pharmaceutical ingredients across borders using fraudulent customs declarations. These raw materials are then clandestinely manufactured in backyard facilities and distributed via social media, unlicensed websites, and doorstep courier services, making them exceptionally difficult to trace or hold accountable for adverse events.
Despite fears of repercussions for purchasing goods through unofficial channels, Fafudi implored the public to report any adverse health reactions or suspicious vendors to authorities. SAHPRA’s market surveillance team actively monitors digital spaces, but relies heavily on tips from concerned healthcare workers and citizens to identify and investigate unlawful practitioners and counterfeit distributors.
“You cannot inject something when you do not know what it is,” Fafudi cautioned, reinforcing that safety, efficacy, and quality evaluations are the sole domain of registered healthcare facilities. She urged the public to stop taking chances with unverified products and to always confirm the authorization status of any facility before seeking medical treatment.